Castle Biosciences Drops 16.8% as RSI Signals Oversold and Analyst Estimates Rise
Castle Biosciences shares have fallen 16.8% over the past four weeks, putting the stock into oversold RSI territory. Meanwhile, analysts have lifted full-year loss-per-share forecasts from $1.06 to $0.96, indicating potential for a technical trend reversal.
1. Technical Indicators Show Oversold Conditions
Castle Biosciences’ relative strength index has dipped below 30, marking an oversold condition for the first time in several months. The 16.8% share decline over four weeks suggests selling pressure may have peaked, creating a potential entry point for short-term momentum traders.
2. Analysts Narrow Loss Forecasts
Consensus full-year loss-per-share estimates have narrowed from $1.06 to $0.96 over the past two months. Several analysts have upgraded ratings, reflecting improved sentiment as the company approaches key clinical and revenue catalysts later this year.